Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2015 - 2023)

Cartesian Therapeutics (RNAC) has 9 years of Non-Current Deffered Revenue data on file, last reported at $3.5 million in Q4 2023.

• Non-Current Deffered Revenue for Q4 2023 came in at $3.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $3.5 million (changed N/A YoY), and the FY2023 annual result was $3.5 million, changed N/A from the prior year.
• Non-Current Deffered Revenue eased to $3.5 million in Q4 2023 per RNAC's latest filing, from $4.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $51.5 million in Q3 2020 and troughed at $3.5 million in Q4 2023.
• A 5-year average of $16.4 million and a median of $14.7 million in 2019 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2019 and 2022: Non-Current Deffered Revenue surged 22259.7% in 2019, then tumbled 72.9% in 2022.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $14.7 million in 2019, then surged by 163.94% to $38.7 million in 2020, then plunged by 70.53% to $11.4 million in 2021, then tumbled by 52.39% to $5.4 million in 2022, then tumbled by 34.92% to $3.5 million in 2023.
• Business Quant data shows RNAC's Non-Current Deffered Revenue at $3.5 million in Q4 2023, $4.0 million in Q3 2023, and $4.9 million in Q2 2023.